Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Effect of heated mittens on physical hand function in people with hand osteoarthritis: randomised controlled trial.

Name: Kaimen Rigor review — Effect of heated mittens on physical hand function in people with hand osteoarthritis: randomised controlled trial.
Item: Effect of heated mittens on physical hand function in people with hand osteoarthritis: randomised controlled trial.
Rating: 96
Author: Alpha1

Bartholdy C, Døssing A, Stisen ZR, Nielsen SM, Christensen R, Danneskiold-Samsøe B, Bliddal H, Henriksen M, Ellegaard K

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 2.75★ (Weak), 0 critical, 3 high issues for “Effect of heated mittens on physical hand function in people with hand osteoarthritis: randomised controlled trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Read alongside

Effect of heated mittens on physical hand function in people with hand osteoarthritis: randomised controlled trial.

Bartholdy C, Døssing A, Stisen ZR, Nielsen SM, Christensen R, Danneskiold-Samsøe B, Bliddal H, Henriksen M, Ellegaard K

Read full text (PMC)

DOI

10.1136/bmj-2023-078222

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/41f80e39-1875-4933-854a-84898c24e7e6" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/41f80e39-1875-4933-854a-84898c24e7e6/badge" alt="Kaimen Rigor review — 2.75★ (Weak), 0 critical, 3 high issues for “Effect of heated mittens on physical hand function in people with hand osteoarthritis: randomised controlled trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

131689073de52fb7a272b4f8e5863492849e3dd1e39945013d365c23ca344631

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Effect of heated mittens on physical hand function in people with hand osteoarthritis: randomised controlled trial.

Bartholdy C, Døssing A, Stisen ZR, Nielsen SM, Christensen R, Danneskiold-Samsøe B, Bliddal H, Henriksen M, Ellegaard K

Paper source

Effect of heated mittens on physical hand function in people with hand osteoarthritis: randomised controlled trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 15 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.
No data or code availability links were detected to verify.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary outcome is the AUSCAN function subscale, a patient-reported measure of physical function, which is a surrogate for clinical benefit. The paper does not provide evidence of target engagement at the tested dose (e.g., skin temperature measurements) nor does it cite validated evidence linking changes in AUSCAN function to hard clinical outcomes. The minimal clinically important difference is not established, and the observed difference of 3.0 points is below the estimated 8-point target used for powering.
“The primary outcome was change in hand function measured on the function subscale of the Australian/Canadian hand osteoarthritis index (AUSCAN; score 0-100 points) at six weeks.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary outcome showed a between-group difference of 3.0 points (95% CI -0.4 to 6.3; P=0.09), which was not statistically significant and is below the minimal clinically important difference of 4 points for within-group changes and the 8-point target used for powering. The paper itself notes the trial may have been underpowered for small but potentially clinically relevant differences.
“The between group difference for change in AUSCAN function at week 6 was 3.0 points (95% confidence interval (CI) −0.4 to 6.3; P=0.09) in favour of heated mittens.”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found · partly checked 06Copyedit6 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and well-reported randomized controlled trial with rigorous design, clear ethical approvals, and appropriate statistical methods. The main weakness is the vague data availability statement, which lacks a concrete access mechanism, and a few minor copyedit issues including an inverted confidence interval and a percentage typo in Table 1.

Both reviewers agreed on all dimensions and study type (interventional RCT); no divergence to reconcile. The statistics verification covered only 1 test (limited coverage), so most statistical results remain unverified but not flagged as problematic. The copyedit pass flagged minor issues, and the integrity check noted two internal contradictions (inverted CI and Table 1 percentage) that are likely typographical.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.

Overstated conclusions

2 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

3 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The paper cites prior research on heat therapy and systematic reviews, acknowledges the low quality of underlying trials, and notes the lack of consensus. It clearly links the premise to the study objective and states a hypothesis. Limitations of prior research are addressed by noting the need for higher-quality trials and the practical advantages of mittens.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The introduction establishes the clinical problem, reviews prior evidence on heat therapy, and provides a clear rationale and hypothesis for the trial.

Evidence

“Systematic reviews looked at the effect of these treatments, with the overall conclusion that a symptom moderating effect was possible.”

Introduction ¶3Find in source

“We hypothesised that wearing heated mittens would result in greater improvement in hand function and relief of symptoms than wearing control mittens in people with hand osteoarthritis.”

IntroductionFind in source

“The recommendation was conditional based on the limited number and low methodological quality of the underlying randomised controlled trials.”

Introduction ¶3Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise by citing prior research on heat therapy for osteoarthritis, acknowledging its limitations, and providing a logical rationale for the study.

Evidence

“Systematic reviews looked at the effect of these treatments, with the overall conclusion that a symptom moderating effect was possible.”

Introduction ¶3Find in source

“The recommendation was conditional based on the limited number and low methodological quality of the underlying randomised controlled trials.”

Introduction ¶3Find in source

“The use of heated mittens as a symptom moderation tool to treat hand osteoarthritis has never been tested.”

Introduction ¶4Find in source

Randomization used permuted random blocks of variable sizes, with allocation concealment via a masked third party. Blinding was attempted but not successful, which is acknowledged. A priori sample size calculation is provided. Inclusion/exclusion criteria are described, and the analysis populations (ITT and per-protocol) are defined. Missing data handling is specified. The trial is a single pivotal trial, so independent replication is not applicable.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial is rigorously designed with adequate randomization, allocation concealment, masking attempts, sample size calculation, and pre-specified analysis populations.

Evidence

“we randomised participants in a 1:1 ratio based on permuted random blocks of variable sizes (2-6 in each block) generated before enrolment.”

MethodsFind in source

paraphrase[Methods, Randomisation and masking]

“Masking was maintained until the trial database was locked and all analyses ... had been done and interpreted.”

“180 participants providing 80.2% power to detect an 8 point mean difference in AUSCAN function scores.”

MethodsFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous: randomization method, allocation concealment, masking attempts, sample size calculation, and pre-specified analysis populations are all described.

Evidence

“we randomised participants in a 1:1 ratio based on permuted random blocks of variable sizes (2-6 in each block) generated before enrolment.”

MethodsFind in source

“The mittens were coded A or B to conceal the allocation from participants, clinical and non-clinical staff, and outcome assessors.”

MethodsFind in source

“180 participants providing 80.2% power to detect an 8 point mean difference in AUSCAN function scores.”

MethodsFind in source

The study reports age, sex, BMI, and disease duration in the results and baseline table. Since both sexes are enrolled, sex justification is not applicable. Species/strain and housing conditions are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are well reported, including age, sex, BMI, and disease duration.

Evidence

“87% (n=173) were women”

ResultsFind in source

paraphrase[Results, Participant characteristics]

“The mean age of participants was 71 years, ... and mean body mass index was 24.9 (SD 4.4).”

“Median disease duration was 10 years (interquartile range 5-15 years).”

ResultsFind in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including age, sex, BMI, disease duration, and baseline outcomes.

Evidence

“87% (n=173) were women”

ResultsFind in source

paraphrase[Results, Participant characteristics]

“The mean age of participants was 71 years, ... and mean body mass index was 24.9 (SD 4.4).”

“Median disease duration was 10 years (interquartile range 5-15 years).”

ResultsFind in source

The paper states that the project was deemed exempt from approval by the local Health Research Ethics Committee (ref: 20020569) and approved by the Danish Data Security Agency (ref: P-2020-670). Informed consent is mentioned in the Methods. Regulatory compliance is implied through adherence to Danish regulations.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approval and consent are adequately documented, with named committees and references.

Evidence

“This project was deemed exempt from approval by the local Health Research Ethics Committee (ref: 20020569) and did not require approval from the Danish Medical Equipment Board (ref: 2020030890).”

EthicsFind in source

“All participants provided signed informed consent before trial participation.”

MethodsFind in source

“The project was approved by the Danish Data Security Agency before the patients first visit (ref: P-2020-670).”

EthicsFind in source

PASSReviewer 2· 95% conf

Ethical approval and consent are adequately documented, including a named ethics committee and informed consent.

Evidence

“This project was deemed exempt from approval by the local Health Research Ethics Committee (ref: 20020569)”

EthicsFind in source

“All participants provided signed informed consent before trial participation.”

MethodsFind in source

“The project was approved by the Danish Data Security Agency before the patients first visit (ref: P-2020-670).”

EthicsFind in source

The mittens are identified as commercially available from Nordic Heat, Denmark, with a description of the heating element and control mechanism. The statistical software (R and SAS) is identified. No other biological or chemical resources are used, so other sub-criteria are not applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (mittens) is identified with manufacturer and details, and the statistical software is named.

Evidence

“The mittens used in this trial are commercially available (Nordic Heat, Denmark).”

MethodsFind in source

“The statistical analysis was performed using R (version 4.0.3) and SAS studio.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational product (heated mittens) is identified with manufacturer and technical details, and the statistical software is named.

Evidence

“The mittens used in this trial are commercially available (Nordic Heat, Denmark).”

MethodsFind in source

“bilateral measures of grip strength using a dynamometer (Grippit; Detektor, Gothenburg, Sweden)”

MethodsFind in source

“The statistical analysis was performed using R (version 4.0.3) and SAS studio.”

Statistical analysisFind in source

The primary analysis uses mixed linear models with adjustment for baseline, and secondary outcomes use ANCOVA with multiple imputation. Effect sizes with 95% CIs are reported for all outcomes. Exact p-values are given for the primary outcome; secondary outcomes are reported with CIs only, which is acceptable. Software is identified. Data presentation includes per-group n and appropriate figures. Mathematical plausibility checks were not possible for all values, but no obvious errors were found.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well described, with effect sizes and confidence intervals reported; p-values are provided for the primary outcome.

Evidence

paraphrase[Methods, Statistical analysis]

“Continuous outcomes with repeated measures ... were analysed using repeated measures mixed linear models”

“The mean between group difference was 3.0 points (95% CI −0.4 to 6.3; P=0.09)”

ResultsFind in source

“The statistical analysis was performed using R (version 4.0.3) and SAS studio.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well described, with effect sizes and confidence intervals reported; p-values are exact where reported.

Evidence

“Continuous outcomes with repeated measures (ie, AUSCAN pain, function, and stiffness subscales) were analysed using repeated measures mixed linear models”

Statistical analysisFind in source

“The mean between group difference was 3.0 points (95% CI −0.4 to 6.3; P=0.09)”

ResultsFind in source

“The statistical analysis was performed using R (version 4.0.3) and SAS studio.”

Statistical analysisFind in source

The data availability statement is present but does not specify a repository, platform, or conditions for access. It only provides an email address. Since the trial involves patient data, repository deposit and accession numbers are not applicable. No custom code is mentioned, so code sharing is not applicable.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 90% conf

A data availability statement exists but is vague, offering data 'upon reasonable request' without a clear mechanism or timeframe.

Evidence

“Data will be made available upon reasonable request to the corresponding author at cecilie.bartholdy.skjaldgaard@regionh.dk.”

Data availabilityFind in source

WARNReviewer 2· 90% conf

A data availability statement exists but is vague, offering data 'upon reasonable request' without a clear mechanism or timeframe.

Evidence

“Data will be made available upon reasonable request to the corresponding author at cecilie.bartholdy.skjaldgaard@regionh.dk.”

Data availabilityFind in source

The trial is registered at ClinicalTrials.gov (NCT04576403). Methods are comprehensive. Limitations are thoroughly discussed, including unsuccessful masking and potential underpowering. Conclusions are proportional to the evidence. Funding sources and competing interests are declared. No reporting guideline is explicitly mentioned, but the paper follows CONSORT-like structure.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial is registered, methods are detailed, limitations are discussed, and funding/COI are disclosed.

Evidence

“Trial registration ClinicalTrials.gov NCT04576403”

AbstractFind in source

“It was not possible to mask the participants throughout the trial, which is a major limitation.”

LimitationsFind in source

“Funding: This trial was supported by the Danish Rheumatism Association (R192-A6735), Bispebjerg and Frederiksberg Hospital research foundation, A.P. Møllers fond (L-2021-00234).”

FundingFind in source

PASSReviewer 2· 95% conf

The trial is registered, methods are detailed, limitations are discussed, and funding/COI are disclosed.

Evidence

“Trial registration ClinicalTrials.gov NCT04576403”

AbstractFind in source

“It was not possible to mask the participants throughout the trial, which is a major limitation.”

LimitationsFind in source

“This trial was supported by the Danish Rheumatism Association (R192-A6735), Bispebjerg and Frederiksberg Hospital research foundation, A.P. Møllers fond (L-2021-00234).”

FundingFind in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found · partly checked

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.

Checked 47 references by DOI: 46 verified — 1 no DOI (shown, not verified).

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly typo, consistency, grammar.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is methodologically robust and generally trustworthy, but readers should weigh the vague data availability statement and the minor internal inconsistencies (inverted CI, Table 1 percentage) as reporting flaws that could warrant a correction or clarification. The primary outcome was null (P=0.09), and conclusions are appropriately proportional, so no major validity threat is apparent.

1.
HIGHcopyedit
Correct the inverted confidence interval in Results, Adherence: the reported '1 day (95% CI 2.5 to 3.8 days)' is impossible because the CI does not contain the point estimate; verify the actual values and fix.
An impossible confidence interval is a demonstrable internal contradiction that undermines the credibility of the reported result and could warrant a correction.
2.
HIGHcopyedit
Fix the percentage for 'Other' analgesics in Table 1 control group: 8 out of 100 should be 8%, not 20%.
A percentage that does not match the count is a factual error in a key table that readers will notice and could raise questions about data accuracy.
3.
HIGHdata code
Enhance the Data availability statement to specify a concrete access mechanism, such as a data repository or a data access committee, with conditions and timeframe, rather than just an email address.
The current 'upon reasonable request' statement is vague and does not meet modern transparency expectations for clinical trial data sharing.
4.
MEDIUMdata code
Consider depositing de-identified participant data in a recognized repository (e.g., Dryad, Zenodo) or provide a detailed data sharing plan in the protocol.
Repository deposit would make the data availability statement actionable and improve reproducibility.
5.
MEDIUMreporting
Explicitly mention adherence to CONSORT guidelines in the Methods or supplement, and provide the CONSORT checklist as supplementary material.
Explicit reporting guideline adherence enhances transparency and is expected for RCTs.
6.
MEDIUMdata code
If custom analysis code was used, share it in a public repository (e.g., GitHub) with a DOI to improve reproducibility.
Sharing analysis code allows independent verification of the statistical methods.
7.
MEDIUMstatistics
Provide exact p-values for all secondary outcomes, or clarify that they are reported with confidence intervals only by design.
Exact p-values for secondary outcomes would improve transparency, though reporting CIs alone is acceptable.
8.
MEDIUMreporting
Report the minimal clinically important difference (MCID) for the primary outcome (AUSCAN function) to aid interpretation of the null result.
Contextualizing the 3.0-point difference against an MCID helps readers judge clinical relevance.
9.
LOWcopyedit
Remove the extra space before the period in Methods, Outcome measures: 'www.womac.com (http://www.womac.com) .'
Minor formatting issue that should be cleaned up.
10.
LOWcopyedit
Hyphenate 'between-group' in the Abstract and throughout for consistency.
Consistent terminology improves readability.
11.
LOWcopyedit
Change 'SAS studio' to 'SAS Studio' in Methods, Statistical analysis for proper capitalization.
Minor capitalization issue.
12.
LOWreporting
In the limitations, discuss the potential impact of unsuccessful masking on the primary outcome more explicitly.
The acknowledged masking failure could bias the primary outcome, and its potential impact should be addressed.

Full text (41,513 chars)Analyzed: Aug 16, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Effect of heated mittens on physical hand function in people with hand osteoarthritis: randomised controlled trial.

Bartholdy C, Døssing A, Stisen ZR, Nielsen SM, Christensen R, Danneskiold-Samsøe B, Bliddal H, Henriksen M, Ellegaard K

Read full text (PMC)

DOI

10.1136/bmj-2023-078222

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/41f80e39-1875-4933-854a-84898c24e7e6" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/41f80e39-1875-4933-854a-84898c24e7e6/badge" alt="Kaimen Rigor review — 2.75★ (Weak), 0 critical, 3 high issues for “Effect of heated mittens on physical hand function in people with hand osteoarthritis: randomised controlled trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

131689073de52fb7a272b4f8e5863492849e3dd1e39945013d365c23ca344631

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 15 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.
No data or code availability links were detected to verify.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary outcome is the AUSCAN function subscale, a patient-reported measure of physical function, which is a surrogate for clinical benefit. The paper does not provide evidence of target engagement at the tested dose (e.g., skin temperature measurements) nor does it cite validated evidence linking changes in AUSCAN function to hard clinical outcomes. The minimal clinically important difference is not established, and the observed difference of 3.0 points is below the estimated 8-point target used for powering.
“The primary outcome was change in hand function measured on the function subscale of the Australian/Canadian hand osteoarthritis index (AUSCAN; score 0-100 points) at six weeks.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary outcome showed a between-group difference of 3.0 points (95% CI -0.4 to 6.3; P=0.09), which was not statistically significant and is below the minimal clinically important difference of 4 points for within-group changes and the 8-point target used for powering. The paper itself notes the trial may have been underpowered for small but potentially clinically relevant differences.
“The between group difference for change in AUSCAN function at week 6 was 3.0 points (95% confidence interval (CI) −0.4 to 6.3; P=0.09) in favour of heated mittens.”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found · partly checked 06Copyedit6 minor suggestions

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.

Overstated conclusions

2 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

3 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The introduction establishes the clinical problem, reviews prior evidence on heat therapy, and provides a clear rationale and hypothesis for the trial.

Evidence

“Systematic reviews looked at the effect of these treatments, with the overall conclusion that a symptom moderating effect was possible.”

Introduction ¶3Find in source

“We hypothesised that wearing heated mittens would result in greater improvement in hand function and relief of symptoms than wearing control mittens in people with hand osteoarthritis.”

IntroductionFind in source

“The recommendation was conditional based on the limited number and low methodological quality of the underlying randomised controlled trials.”

Introduction ¶3Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise by citing prior research on heat therapy for osteoarthritis, acknowledging its limitations, and providing a logical rationale for the study.

Evidence

“Systematic reviews looked at the effect of these treatments, with the overall conclusion that a symptom moderating effect was possible.”

Introduction ¶3Find in source

“The recommendation was conditional based on the limited number and low methodological quality of the underlying randomised controlled trials.”

Introduction ¶3Find in source

“The use of heated mittens as a symptom moderation tool to treat hand osteoarthritis has never been tested.”

Introduction ¶4Find in source

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial is rigorously designed with adequate randomization, allocation concealment, masking attempts, sample size calculation, and pre-specified analysis populations.

Evidence

“we randomised participants in a 1:1 ratio based on permuted random blocks of variable sizes (2-6 in each block) generated before enrolment.”

MethodsFind in source

paraphrase[Methods, Randomisation and masking]

“Masking was maintained until the trial database was locked and all analyses ... had been done and interpreted.”

“180 participants providing 80.2% power to detect an 8 point mean difference in AUSCAN function scores.”

MethodsFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous: randomization method, allocation concealment, masking attempts, sample size calculation, and pre-specified analysis populations are all described.

Evidence

“we randomised participants in a 1:1 ratio based on permuted random blocks of variable sizes (2-6 in each block) generated before enrolment.”

MethodsFind in source

“The mittens were coded A or B to conceal the allocation from participants, clinical and non-clinical staff, and outcome assessors.”

MethodsFind in source

“180 participants providing 80.2% power to detect an 8 point mean difference in AUSCAN function scores.”

MethodsFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are well reported, including age, sex, BMI, and disease duration.

Evidence

“87% (n=173) were women”

ResultsFind in source

paraphrase[Results, Participant characteristics]

“The mean age of participants was 71 years, ... and mean body mass index was 24.9 (SD 4.4).”

“Median disease duration was 10 years (interquartile range 5-15 years).”

ResultsFind in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including age, sex, BMI, disease duration, and baseline outcomes.

Evidence

“87% (n=173) were women”

ResultsFind in source

paraphrase[Results, Participant characteristics]

“The mean age of participants was 71 years, ... and mean body mass index was 24.9 (SD 4.4).”

“Median disease duration was 10 years (interquartile range 5-15 years).”

ResultsFind in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approval and consent are adequately documented, with named committees and references.

Evidence

EthicsFind in source

“All participants provided signed informed consent before trial participation.”

MethodsFind in source

“The project was approved by the Danish Data Security Agency before the patients first visit (ref: P-2020-670).”

EthicsFind in source

PASSReviewer 2· 95% conf

Ethical approval and consent are adequately documented, including a named ethics committee and informed consent.

Evidence

“This project was deemed exempt from approval by the local Health Research Ethics Committee (ref: 20020569)”

EthicsFind in source

“All participants provided signed informed consent before trial participation.”

MethodsFind in source

“The project was approved by the Danish Data Security Agency before the patients first visit (ref: P-2020-670).”

EthicsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (mittens) is identified with manufacturer and details, and the statistical software is named.

Evidence

“The mittens used in this trial are commercially available (Nordic Heat, Denmark).”

MethodsFind in source

“The statistical analysis was performed using R (version 4.0.3) and SAS studio.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational product (heated mittens) is identified with manufacturer and technical details, and the statistical software is named.

Evidence

“The mittens used in this trial are commercially available (Nordic Heat, Denmark).”

MethodsFind in source

“bilateral measures of grip strength using a dynamometer (Grippit; Detektor, Gothenburg, Sweden)”

MethodsFind in source

“The statistical analysis was performed using R (version 4.0.3) and SAS studio.”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well described, with effect sizes and confidence intervals reported; p-values are provided for the primary outcome.

Evidence

paraphrase[Methods, Statistical analysis]

“Continuous outcomes with repeated measures ... were analysed using repeated measures mixed linear models”

“The mean between group difference was 3.0 points (95% CI −0.4 to 6.3; P=0.09)”

ResultsFind in source

“The statistical analysis was performed using R (version 4.0.3) and SAS studio.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well described, with effect sizes and confidence intervals reported; p-values are exact where reported.

Evidence

“Continuous outcomes with repeated measures (ie, AUSCAN pain, function, and stiffness subscales) were analysed using repeated measures mixed linear models”

Statistical analysisFind in source

“The mean between group difference was 3.0 points (95% CI −0.4 to 6.3; P=0.09)”

ResultsFind in source

“The statistical analysis was performed using R (version 4.0.3) and SAS studio.”

Statistical analysisFind in source

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 90% conf

A data availability statement exists but is vague, offering data 'upon reasonable request' without a clear mechanism or timeframe.

Evidence

“Data will be made available upon reasonable request to the corresponding author at cecilie.bartholdy.skjaldgaard@regionh.dk.”

Data availabilityFind in source

WARNReviewer 2· 90% conf

A data availability statement exists but is vague, offering data 'upon reasonable request' without a clear mechanism or timeframe.

Evidence

“Data will be made available upon reasonable request to the corresponding author at cecilie.bartholdy.skjaldgaard@regionh.dk.”

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial is registered, methods are detailed, limitations are discussed, and funding/COI are disclosed.

Evidence

“Trial registration ClinicalTrials.gov NCT04576403”

AbstractFind in source

“It was not possible to mask the participants throughout the trial, which is a major limitation.”

LimitationsFind in source

“Funding: This trial was supported by the Danish Rheumatism Association (R192-A6735), Bispebjerg and Frederiksberg Hospital research foundation, A.P. Møllers fond (L-2021-00234).”

FundingFind in source

PASSReviewer 2· 95% conf

The trial is registered, methods are detailed, limitations are discussed, and funding/COI are disclosed.

Evidence

“Trial registration ClinicalTrials.gov NCT04576403”

AbstractFind in source

“It was not possible to mask the participants throughout the trial, which is a major limitation.”

LimitationsFind in source

“This trial was supported by the Danish Rheumatism Association (R192-A6735), Bispebjerg and Frederiksberg Hospital research foundation, A.P. Møllers fond (L-2021-00234).”

FundingFind in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found · partly checked

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.

Checked 47 references by DOI: 46 verified — 1 no DOI (shown, not verified).

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly typo, consistency, grammar.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHcopyedit
Correct the inverted confidence interval in Results, Adherence: the reported '1 day (95% CI 2.5 to 3.8 days)' is impossible because the CI does not contain the point estimate; verify the actual values and fix.
An impossible confidence interval is a demonstrable internal contradiction that undermines the credibility of the reported result and could warrant a correction.
2.
HIGHcopyedit
Fix the percentage for 'Other' analgesics in Table 1 control group: 8 out of 100 should be 8%, not 20%.
A percentage that does not match the count is a factual error in a key table that readers will notice and could raise questions about data accuracy.
3.
HIGHdata code
Enhance the Data availability statement to specify a concrete access mechanism, such as a data repository or a data access committee, with conditions and timeframe, rather than just an email address.
The current 'upon reasonable request' statement is vague and does not meet modern transparency expectations for clinical trial data sharing.
4.
MEDIUMdata code
Consider depositing de-identified participant data in a recognized repository (e.g., Dryad, Zenodo) or provide a detailed data sharing plan in the protocol.
Repository deposit would make the data availability statement actionable and improve reproducibility.
5.
MEDIUMreporting
Explicitly mention adherence to CONSORT guidelines in the Methods or supplement, and provide the CONSORT checklist as supplementary material.
Explicit reporting guideline adherence enhances transparency and is expected for RCTs.
6.
MEDIUMdata code
If custom analysis code was used, share it in a public repository (e.g., GitHub) with a DOI to improve reproducibility.
Sharing analysis code allows independent verification of the statistical methods.
7.
MEDIUMstatistics
Provide exact p-values for all secondary outcomes, or clarify that they are reported with confidence intervals only by design.
Exact p-values for secondary outcomes would improve transparency, though reporting CIs alone is acceptable.
8.
MEDIUMreporting
Report the minimal clinically important difference (MCID) for the primary outcome (AUSCAN function) to aid interpretation of the null result.
Contextualizing the 3.0-point difference against an MCID helps readers judge clinical relevance.
9.
LOWcopyedit
Remove the extra space before the period in Methods, Outcome measures: 'www.womac.com (http://www.womac.com) .'
Minor formatting issue that should be cleaned up.
10.
LOWcopyedit
Hyphenate 'between-group' in the Abstract and throughout for consistency.
Consistent terminology improves readability.
11.
LOWcopyedit
Change 'SAS studio' to 'SAS Studio' in Methods, Statistical analysis for proper capitalization.
Minor capitalization issue.
12.
LOWreporting
In the limitations, discuss the potential impact of unsuccessful masking on the primary outcome more explicitly.
The acknowledged masking failure could bias the primary outcome, and its potential impact should be addressed.

Full text (41,513 chars)Analyzed: Aug 16, 2026